Twenty-seven patients with measurable, advanced nonsquamous cell carcinoma of the cervix were entered into this Phase II study evaluating the efficacy of ICRF-159 (razoxane). Eighteen of the 27 had adenocarcinoma. Thirteen patients had no previous chemotherapy. One patient was ineligible because she was never treated. One patient was inevaluable for response. Thus, 25 evaluable patients were given ICRF-159 orally at a starting dose of 1.5 g/m2 weekly until response could be determined. Grade 4 hematologic toxicity in two patients was the only life-threatening toxicity. One study patient had a partial response, 13 patients were regarded as having stable disease, and 11 had increasing disease. We conclude that ICRF-159 administered at this dose and schedule has no significant clinical activity against advanced adenocarcinoma of the cervix.